Samuel Yamshon is an Oncology physician affiliated with Cornell University. OpenAlex indexes 66 publications with 431 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 E 70th St
Starr 3
New York, NY 10021
Telephone
646-962-7950Provider last certified this registry record 31 Jul 2023.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Gilead Sciences, Inc.Program year20252 payments
- Genmab U.S., Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-World (RW) Study of the Effectiveness, Safety, and Health Care Resource Utilization (HCRU) of Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) in the Second-Line (2L) Treatment Setting
Biology of Blood and Marrow Transplantation
2026 - Integrating Low-Dose Total Body Irradiation into Lymphodepletion Enhances CD19 CAR T-cell Therapy for Large B-cell Lymphoma
Biology of Blood and Marrow Transplantation
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Devereux, MD
Cornell University
Thomas Walsh, MD
Cornell University
Cora Sternberg, MD
Cornell University
George Alexopoulos, MD
Cornell University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”